Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
2(29%)
Results Posted
25%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
1
14%
Ph phase_2
5
71%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Active, not recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 25 (71.4%)
Phase 31 (14.3%)

Trials by Status

active_not_recruiting114%
recruiting114%
completed457%
terminated114%

Recent Activity

2 active trials
Showing 5 of 7
active_not_recruitingphase_1

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

NCT02629120
recruitingphase_2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

NCT03520647
completedphase_2

Haploidentical Donor vs mMUD in Hematological Malignancies

NCT03275636
completedphase_2

Allo HSCT Using RIC for Hematological Diseases

NCT02661035
terminatedphase_3

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

NCT01445821
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02629120Phase 1

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

Active Not Recruiting
NCT03520647Phase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Recruiting
NCT03275636Phase 2

Haploidentical Donor vs mMUD in Hematological Malignancies

Completed
NCT02661035Phase 2

Allo HSCT Using RIC for Hematological Diseases

Completed
NCT01445821Phase 3

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

Terminated
NCT01039025Phase 2

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

Completed
NCT00002221Phase 2

Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7